PURPOSE: To determine the effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. DESIGN: Prospective randomized open-labeled interventional clinical trial. METHODS: A total of 124 patients with a history of recurrent toxoplasmic retinochoroiditis were randomized to treatment with one tablet of trimethoprim (160 mg)/sulfamethoxazole (800 mg) (Bactrim F; Roche Pharmaceuticals, Rio de Janeiro, Brazil) every 3 days (61 patients) or to observation without treatment (63 patients) and were followed monthly for up to 20 consecutive months for clinical signs of disease recurrence. A recurrence was defined as a new focus of necrotizing retinochoroiditis with active inflammation either adjacent to or remote from preexisting retinochoroidal scars. RESULTS:Recurrences developed in four (6.6%) treated patients and in 15 (23.8%) controls (P =.01). Treatment was discontinued prematurely in four patients because of mild drug reactions. CONCLUSION: Long-term intermittent treatment with trimethoprim/sulfamethoxazole can reduce the rate of recurrent toxoplasmic retinochoroiditis.
RCT Entities:
PURPOSE: To determine the effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. DESIGN: Prospective randomized open-labeled interventional clinical trial. METHODS: A total of 124 patients with a history of recurrent toxoplasmic retinochoroiditis were randomized to treatment with one tablet of trimethoprim (160 mg)/sulfamethoxazole (800 mg) (Bactrim F; Roche Pharmaceuticals, Rio de Janeiro, Brazil) every 3 days (61 patients) or to observation without treatment (63 patients) and were followed monthly for up to 20 consecutive months for clinical signs of disease recurrence. A recurrence was defined as a new focus of necrotizing retinochoroiditis with active inflammation either adjacent to or remote from preexisting retinochoroidal scars. RESULTS: Recurrences developed in four (6.6%) treated patients and in 15 (23.8%) controls (P =.01). Treatment was discontinued prematurely in four patients because of mild drug reactions. CONCLUSION: Long-term intermittent treatment with trimethoprim/sulfamethoxazole can reduce the rate of recurrent toxoplasmic retinochoroiditis.
Authors: Leila Shobab; Uwe Pleyer; Joerdis Johnsen; Sylvia Metzner; Erick R James; N Torun; Michael P Fay; Oliver Liesenfeld; Michael E Grigg Journal: J Infect Dis Date: 2013-07-21 Impact factor: 5.226
Authors: Laura Phan; Kristen Kasza; Jessica Jalbrzikowski; A Gwendolyn Noble; Paul Latkany; Annie Kuo; William Mieler; Sanford Meyers; Peter Rabiah; Kenneth Boyer; Charles Swisher; Marilyn Mets; Nancy Roizen; Simone Cezar; Mari Sautter; Jack Remington; Paul Meier; Rima McLeod Journal: Am J Ophthalmol Date: 2008-07-10 Impact factor: 5.258
Authors: P Valentini; D Buonsenso; G Barone; D Serranti; R Calzedda; M Ceccarelli; D Speziale; R Ricci; L Masini Journal: J Perinatol Date: 2014-09-11 Impact factor: 2.521